lenalidomide has been researched along with vitamin k semiquinone radical in 1 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (vitamin k semiquinone radical) | Trials (vitamin k semiquinone radical) | Recent Studies (post-2010) (vitamin k semiquinone radical) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 12,827 | 491 | 3,703 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chalayer, E; Chapelle, C; Elalamy, I; Laporte, S; Leleu, X; Tardy, B | 1 |
1 other study(ies) available for lenalidomide and vitamin k semiquinone radical
| Article | Year |
|---|---|
Does the choice of thrombotic prophylactic drug depend on the known risk factors of patients with multiple myeloma in clinical practice?
Topics: Aged; Angiogenesis Inhibitors; Anticoagulants; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Lenalidomide; Male; Multiple Myeloma; Risk Factors; Thalidomide; Thrombosis; Vitamin K | 2016 |